Close

BofA/Merrill Lynch Downgrades Eli Lilly (LLY) to Neutral, Upside Priced In

January 9, 2015 6:35 AM EST
Get Alerts LLY Hot Sheet
Price: $783.00 +0.62%

Rating Summary:
    24 Buy, 8 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 11 | New: 11
Join SI Premium – FREE

BofA/Merrill Lynch downgraded Eli Lilly (NYSE: LLY) from Buy to Neutral with a price target of $74.00 (from $70.00), saying 2015 positives are already priced in.

Analyst Colin Bristow said while they remain constructive on the company and expect solid launches for Trulicity, Jardiance and Cyramza, they believe the current valuation already reflects this. Solanezumab (Alzhimer's) and evacetrapib (CV risk reduction) provided the next leg of upside but there will unlikely be meaningful data in 2015.

For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.

Shares of Eli Lilly closed at $70.87 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst PT Change, Downgrades, FDA